Thomas F. Kirk Buys 7,400 Shares of Myomo, Inc. (NYSEAMERICAN:MYO) Stock

Myomo, Inc. (NYSEAMERICAN:MYO) Director Thomas F. Kirk bought 7,400 shares of the stock in a transaction dated Thursday, March 13th. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $37,000.00. Following the completion of the transaction, the director now directly owns 255,933 shares of the company’s stock, valued at $1,279,665. This trade represents a 2.98 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Myomo Trading Up 2.4 %

Shares of NYSEAMERICAN:MYO opened at $5.19 on Friday. Myomo, Inc. has a 1-year low of $2.51 and a 1-year high of $7.17. The firm has a market cap of $157.00 million, a price-to-earnings ratio of -22.57 and a beta of 1.68.

Institutional Investors Weigh In On Myomo

Large investors have recently made changes to their positions in the business. Barclays PLC purchased a new stake in shares of Myomo during the 3rd quarter valued at $36,000. BNP Paribas Financial Markets purchased a new stake in shares of Myomo during the 4th quarter valued at $64,000. Walleye Capital LLC purchased a new stake in Myomo in the 4th quarter worth about $66,000. Squarepoint Ops LLC purchased a new stake in Myomo in the 4th quarter worth about $74,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Myomo in the 4th quarter worth about $95,000. 44.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on MYO shares. Alliance Global Partners reaffirmed a “buy” rating on shares of Myomo in a research report on Tuesday. HC Wainwright raised their price objective on Myomo from $7.50 to $9.50 and gave the company a “buy” rating in a research note on Wednesday. Finally, Craig Hallum raised their price objective on Myomo from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $9.25.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.